Prism MarketView

January 08, 2024 at 1:42 pm

Johnson & Johnson Acquires Ambrx in $2B Win for Advanced Prostate Cancer

Biopharmaceutical company, Ambrx (Nasdaq: AMAM), has announced it will be acquired by Johnson & Johnson for $28.00 per share in cash, for a total equity… [Read More]

January 02, 2024 at 1:24 pm

Better Therapeutics Targets FDA Breakthrough Device Designation for Liver Disease Treatment

Prescription digital therapeutics (PDTs) pioneer, Better Therapeutics (Nasdaq: BTTX), has submitted a request to the FDA for Breakthrough Device Designation for its novel PDT designed… [Read More]

December 20, 2023 at 9:04 am

First Dosing in Clinical Trial to Trigger $10M Payment for Compugen; Share Price Skyrockets 170%

Cancer immunotherapy company, Compugen Ltd (Nasdaq: CGEN) will be eligible to receive a milestone payment of $10 million from AstraZeneca (Nasdaq: AZN) when the first… [Read More]

December 19, 2023 at 3:13 pm

BioStem Technologies Strengthens Board of Directors with Key Appointments

BioStem Technologies (OTC: BSEM) has strengthened its Board of Directors this week with the appointment of industry veterans, Mr. Thomas Dugan as Chairman and Mr…. [Read More]

December 13, 2023 at 12:55 pm

FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%

ReShape Lifesciences (Nasdaq: RSLS) has been granted FDA approval of a PMA supplement for the company’s next generation, enhanced Lap-Band® 2.0 FLEX. The company’s share… [Read More]

December 12, 2023 at 10:07 am

Anixa Advances Breast Cancer Vaccine

Anixa Biosciences, Inc. (Nasdaq: ANIX) has reported positive results from a Phase 1 clinical trial of its breast cancer vaccine for Triple Negative breast cancer… [Read More]

October 17, 2023 at 1:27 pm

SELLAS Announces Positive Initial Topline Data in Acute Myeloid Leukemia Patients

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive initial topline data from its ongoing Phase 2a clinical trial of its novel and highly… [Read More]

October 03, 2023 at 8:19 am

Vistagen Announces $100M Underwritten Offer to Fund Social Anxiety Drug Program

Vistagen Therapeutics (Nasdaq: VTGN) has announced the pricing of a $100 million underwritten offering of its common stock and warrants. Vistagen intends to use the… [Read More]

October 02, 2023 at 4:34 pm

Next-Gen Bipolar Disorder Treatment Progressing, Says Alzamend

Clinical stage biopharmaceutical company, Alzamend Neuro (Nasdaq: ALZN), has received a “Study May Proceed” letter from the FDA for a Phase IIA clinical study of… [Read More]

Tag: BioTech